DK2183263T3 - Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer - Google Patents

Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer

Info

Publication number
DK2183263T3
DK2183263T3 DK08826634.1T DK08826634T DK2183263T3 DK 2183263 T3 DK2183263 T3 DK 2183263T3 DK 08826634 T DK08826634 T DK 08826634T DK 2183263 T3 DK2183263 T3 DK 2183263T3
Authority
DK
Denmark
Prior art keywords
transporter
inhibitors
preparation
methods
compounds useful
Prior art date
Application number
DK08826634.1T
Other languages
English (en)
Inventor
Jie Yan
Shinya Iimura
Ross Mabon
Haiming Zhang
Nicole Cathleen Goodwin
Bryce Alden Harrison
Qiuling Song
Wenxue Wu
Matthew Mangzhu Zhao
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2183263T3 publication Critical patent/DK2183263T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08826634.1T 2007-07-26 2008-07-17 Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer DK2183263T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95212207P 2007-07-26 2007-07-26
PCT/US2008/070250 WO2009014970A1 (en) 2007-07-26 2008-07-17 Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors

Publications (1)

Publication Number Publication Date
DK2183263T3 true DK2183263T3 (da) 2012-01-30

Family

ID=39877996

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08826634.1T DK2183263T3 (da) 2007-07-26 2008-07-17 Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer

Country Status (23)

Country Link
US (2) US8026347B2 (da)
EP (1) EP2183263B1 (da)
JP (2) JP5653213B2 (da)
KR (1) KR101663324B1 (da)
CN (1) CN101801989B (da)
AR (2) AR067701A1 (da)
AT (1) ATE530558T1 (da)
AU (1) AU2008279424B2 (da)
CA (1) CA2694029C (da)
CL (1) CL2008002169A1 (da)
CO (1) CO6260141A2 (da)
DK (1) DK2183263T3 (da)
EA (1) EA017411B1 (da)
EC (1) ECSP109987A (da)
ES (1) ES2375800T3 (da)
IL (1) IL203209A (da)
NZ (1) NZ582536A (da)
PL (1) PL2183263T3 (da)
PT (1) PT2183263E (da)
TW (2) TWI506024B (da)
UA (1) UA107175C2 (da)
WO (1) WO2009014970A1 (da)
ZA (1) ZA201000219B (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
CN102149280B (zh) 2008-07-15 2017-05-24 泰拉科斯有限公司 氘化苄基苯衍生物及其使用方法
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
AP2728A (en) 2008-08-28 2013-08-31 Pfizer Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
DK2496583T3 (da) 2009-11-02 2015-02-02 Pfizer Dioxa-bicyclo[3.2.1]octan-2,3,4-triol derivater
CN105193761B (zh) 2009-11-13 2019-12-06 阿斯利康(瑞典)有限公司 双层片剂
CN102740839B (zh) 2009-11-13 2015-05-06 阿斯利康(瑞典)有限公司 立即释放片剂
US20120294936A1 (en) 2009-11-13 2012-11-22 Astrazeneca Uk Limited Reduced mass metformin formulations
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
MX2013002146A (es) 2010-09-03 2013-04-03 Astrazeneca Uk Ltd Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua.
RU2607480C2 (ru) 2011-02-01 2017-01-10 Бристол-Майерс Сквибб Компани Фармацевтические композиции, содержащие аминосоединение
US9034921B2 (en) 2011-06-01 2015-05-19 Green Cross Corporation Diphenylmethane derivatives as SGLT2 inhibitors
US20130137646A1 (en) 2011-06-03 2013-05-30 Boehringer Ingelheim International Gmbh Methods of treatment, pharmaceutical compositions and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
UA117574C2 (uk) * 2012-11-20 2018-08-27 Лексікон Фармасьютікалз, Інк. Інгібітори котранспортера натрій-глюкози 1
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
EP2895490B1 (en) 2013-09-27 2016-10-19 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
WO2015051484A1 (en) 2013-10-12 2015-04-16 Theracos, Inc. Preparation of hydroxy-benzylbenzene derivatives
CN105828815B (zh) 2013-12-17 2020-03-27 勃林格殷格翰动物保健有限公司 猫科动物中代谢紊乱的治疗
PL3485890T3 (pl) 2014-01-23 2023-08-28 Boehringer Ingelheim Vetmedica Gmbh Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
KR102662473B1 (ko) 2014-04-01 2024-05-03 베링거잉겔하임베트메디카게엠베하 말과 동물에서 대사 장애의 치료
DK3197429T3 (da) 2014-09-25 2024-08-26 Boehringer Ingelheim Vetmedica Gmbh Kombinationsbehandling med sglt2-hæmmere og dopaminagonister til forebyggelse af metaboliske lidelser af dyr i hestefamilien
WO2017202351A1 (zh) * 2016-05-25 2017-11-30 苏州科睿思制药有限公司 一种钠-葡萄糖协同转运蛋白抑制剂药物的新晶型及其制备方法和用途
US10793588B2 (en) * 2016-05-28 2020-10-06 Ji Lin Hui Sheng Bio-Pharmaceutical Co., Ltd. Crystal form of sodium-glucose cotransporter 2 inhibitor
TN2018000437A1 (en) 2016-06-17 2020-06-15 Dae Woong Pharma Method for producing diphenylmethane derivative
EP3528800A1 (en) 2016-10-19 2019-08-28 Boehringer Ingelheim International GmbH Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
CN107540685B (zh) * 2017-09-04 2020-05-05 杭州科巢生物科技有限公司 一种Sotagliflozin的制备方法及其中间体
AU2019254371A1 (en) 2018-04-17 2020-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN108675976B (zh) * 2018-05-14 2020-07-14 浙江宏元药业股份有限公司 一种6-卤代葡萄糖碳苷及其制备方法和应用
BR112021002523A2 (pt) 2018-08-13 2021-05-04 Daewoong Pharmaceutical Co., Ltd. método para preparar um composto
CN110818722B (zh) * 2018-08-14 2022-12-02 苏州鹏旭医药科技有限公司 三种化合物及其制备方法和在合成索格列净中的用途
CN112955215B (zh) 2018-10-29 2024-05-17 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途
CN112955214B (zh) 2018-10-29 2024-05-07 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途
EP3771480A1 (en) * 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Continuous process for preparing the crystalline form ii of sotagliflozin
WO2021105152A1 (en) 2019-11-28 2021-06-03 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors in the drying-off of non-human mammals
BR112022016360A2 (pt) 2020-02-17 2022-10-04 Boehringer Ingelheim Vetmedica Gmbh Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
US20240269105A1 (en) 2021-07-28 2024-08-15 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
WO2023006747A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
EP4376829A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法
CA3256728A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh AQUEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING SGLT-2 INHIBITORS
TW202500160A (zh) 2023-03-06 2025-01-01 德商百靈佳殷格翰維美迪加股份有限公司 用於遞送特別是包含一或多種ｓｇｌｔ—２抑制劑之液體醫藥組合物之系統及方法
TW202508455A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
WO2025160910A1 (en) * 2024-02-01 2025-08-07 New Wish Biotechnology Wuxi Co., Ltd. Indazole compound and pharmaceutical composition, preparation method and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CZ20023023A3 (cs) * 2000-03-17 2003-04-16 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxybenzylbenzenové deriváty, léčivé směsi obsahující tyto látky a meziprodukty pro přípravu derivátů
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
CA2429833A1 (en) * 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ATE318272T1 (de) * 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
US6562791B1 (en) * 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
AU2003234737B2 (en) * 2002-04-12 2009-08-27 Achillion Pharmaceuticals, Inc. Method for synthesizing Beta-L-fluoro-2',3'didehydrocytidine (Beta-L-FD4C)
UA77300C2 (en) * 2002-08-09 2006-11-15 Taisho Pharmaceutical Co Ltd 5-thio-?-d-glucopyranoside derivatives and pharmaceutical composition for treating diabetes
JP2006516257A (ja) * 2003-01-03 2006-06-29 ブリストル−マイヤーズ　スクイブ　カンパニー Ｃ−アリールグルコシドｓｇｌｔ２阻害剤の製造法
US7368475B2 (en) * 2003-03-12 2008-05-06 Kemin Pharma Bvba Furanose-type bicyclic carbohydrates with biological activity
PL1609785T3 (pl) * 2003-03-14 2016-07-29 Astellas Pharma Inc Pochodne c-glikozydowe i ich sole
WO2006018150A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE445608T1 (de) * 2005-02-23 2009-10-15 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008044268A1 (en) * 2006-10-05 2008-04-17 Panasonic Corporation Transmitter apparatus and transmitting method
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法

Also Published As

Publication number Publication date
TWI419886B (zh) 2013-12-21
ECSP109987A (es) 2010-03-31
CN101801989A (zh) 2010-08-11
JP2014001230A (ja) 2014-01-09
ATE530558T1 (de) 2011-11-15
US20090030198A1 (en) 2009-01-29
IL203209A (en) 2014-02-27
CA2694029C (en) 2016-10-04
UA107175C2 (uk) 2014-12-10
CA2694029A1 (en) 2009-01-29
US8293878B2 (en) 2012-10-23
AR112669A2 (es) 2019-11-27
AU2008279424A1 (en) 2009-01-29
PT2183263E (pt) 2012-01-11
HK1143982A1 (zh) 2011-01-21
NZ582536A (en) 2012-01-12
EP2183263B1 (en) 2011-10-26
TW201350473A (zh) 2013-12-16
CN101801989B (zh) 2015-11-25
KR101663324B1 (ko) 2016-10-06
ES2375800T3 (es) 2012-03-06
JP5653213B2 (ja) 2015-01-14
CO6260141A2 (es) 2011-03-22
TWI506024B (zh) 2015-11-01
EA017411B1 (ru) 2012-12-28
EP2183263A1 (en) 2010-05-12
JP5764174B2 (ja) 2015-08-12
BRPI0813840A2 (pt) 2017-06-06
KR20100040869A (ko) 2010-04-21
US20120095197A1 (en) 2012-04-19
AU2008279424B2 (en) 2013-06-13
TW200914434A (en) 2009-04-01
AR067701A1 (es) 2009-10-21
ZA201000219B (en) 2011-03-30
CL2008002169A1 (es) 2009-03-20
WO2009014970A1 (en) 2009-01-29
PL2183263T3 (pl) 2012-03-30
US8026347B2 (en) 2011-09-27
EA201070186A1 (ru) 2010-08-30
JP2010534661A (ja) 2010-11-11

Similar Documents

Publication Publication Date Title
DK2183263T3 (da) Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer
DK2089361T3 (da) Inhibitorer af natriumglucose-cotransportør 2 og fremgangsmåder til deres anvendelse
EP2192838A4 (en) HETEROCYCLIC NEKROPTOSIS HEMMER
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2099796T3 (da) Aza-indolyl-forbindelser og fremgangsmåder for anvendelse
DK2414507T3 (da) Mutanter af aktiveringsinduceret cytidin-deaminase (aid) og til anvendelsesfremgangsmåder
DK2229360T3 (da) Indolinonderivater og fremgangsmåde til deres fremstilling
HRP20150003T1 (xx) Sastavi inhibitora dpp-iv
CY2014012I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK2015754T3 (da) Anvendelse af dpp-iv-inhibitorer
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DK3252057T3 (da) Multicykliske forbindelser og fremgangsmåder til anvendelse deraf
HRP20170222T1 (hr) Kristalni oblik karbamoil-cikloheksan derivata
DK1924577T3 (da) Substituerede benzimidazoler og fremgangsmåder til fremstilling
DK1981863T3 (da) Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater
DK1981875T3 (da) Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
DK2029746T3 (da) Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese
EP2299999A4 (en) STAT3 INHIBITORS
DK2247577T4 (da) Fremgangsmåde til regioselektiv syntese af 1-alkyl-3-haloalkyl-pyrazol-4-carboxylsyrederivater
DK1979326T3 (da) Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
NO20076533L (no) Fremgangsmåte og system for klokkedriftskompensering
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
DK2316010T3 (da) Vævskassette og fremgangsmåde til fremstilling af vævsprøver
NO20085219L (no) Koplingsarrangement og fremgangsmate for forspent sammenkopling
DK1884507T3 (da) Fremgangsmåde til fremstilling af glycerol